Latest News for Gilead Sciences Stock (NASDAQ:GILD)

Wednesday, November 29, 2023

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Vandana Singh - 1 day ago

Tuesday, November 28, 2023

Gilead Sciences Says It Has Fully Cooperated With The U.S. FDA's Request For An Analysis Of Our Data Related To The FDA's Inquiry
Benzinga Newsdesk - 2 days ago
Gilead Sciences Says It Is Confident In The Overall Safety Profile Of Both Tecartus And Yescarta; There Is No Evidence To Date That Treatment With Yescarta Or Tecartus Has A Causal Role In The Development Of New Malignancies
Benzinga Newsdesk - 2 days ago

Wednesday, November 22, 2023

Looking Into Gilead Sciences's Recent Short Interest
Benzinga Insights - Nov 22, 2023, 1:45PM

Tuesday, November 21, 2023

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Benzinga Insights - Nov 21, 2023, 1:30PM
Watching Aurinia Pharmaceuticals; Traders Circulating Gordon Haskett Says Gilead Could Be About To Acquire The Company
Benzinga Newsdesk - Nov 21, 2023, 9:38AM

Friday, November 17, 2023

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
Vandana Singh - Nov 17, 2023, 7:46AM

Wednesday, November 15, 2023

Gilead Sciences's Options: A Look at What the Big Money is Thinking
Benzinga Insights - Nov 15, 2023, 12:16PM
Kite, A Gilead Company, And Arcellx Have Expanded Their Existing Collaboration, Which Was Originally Announced In December 2022, For CART-ddBCMA To Include Lymphomas; Arcellx To Receive $200M Equity Investment And $85M Upfront Cash Payment
Benzinga Newsdesk - Nov 15, 2023, 6:03AM

Tuesday, November 14, 2023

RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $77
Benzinga Newsdesk - Nov 14, 2023, 11:50AM

Thursday, November 09, 2023

Gilead Sciences shares are trading lower. Deutsche Bank initiated coverage on the stock with a Hold rating.
Benzinga Newsdesk - Nov 9, 2023, 2:21PM
A Closer Look at Gilead Sciences's Options Market Dynamics
Benzinga Insights - Nov 9, 2023, 1:32PM
Where Gilead Sciences Stands With Analysts
Benzinga Insights - Nov 9, 2023, 8:00AM
Deutsche Bank Initiates Coverage On Gilead Sciences with Hold Rating, Announces Price Target of $75
Benzinga Newsdesk - Nov 9, 2023, 5:17AM

Wednesday, November 08, 2023

Gilead Sciences shares are trading lower following Q3 earnings.
Benzinga Newsdesk - Nov 8, 2023, 10:34AM

Tuesday, November 07, 2023

Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
Ryan Gustafson - Nov 7, 2023, 4:36PM
Gilead Sees FY23 Non-GAAP EPS $6.65-$6.85 vs $6.25 Est.
Benzinga Newsdesk - Nov 7, 2023, 4:04PM
Gilead Sees FY23 Total Product Sales $26.7B-$26.9B, Up From Prior Range Of $26.3B-$26.7B
Benzinga Newsdesk - Nov 7, 2023, 4:04PM
Gilead Sciences Q3 Adj $2.29 Beats $1.92 Estimate, Sales $7.10B Beat $6.80B Estimate
Benzinga Newsdesk - Nov 7, 2023, 4:03PM
US Stocks Eye Longest Winning Streak In 2 Years, Oil Tumbles: What's Driving Markets Tuesday?
Shanthi Rexaline - Nov 7, 2023, 2:48PM
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Vandana Singh - Nov 7, 2023, 11:17AM
Earnings Scheduled For November 7, 2023
Benzinga Insights - Nov 7, 2023, 6:34AM

Monday, November 06, 2023

Gilead And Arcus Report New Data Showing Encouraging Clinical Activity Of Anti-TIGIT Domvanalimab-Containing Regimen As First-Line Treatment For Upper GI Cancers
Benzinga Newsdesk - Nov 6, 2023, 5:40PM
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today
Benzinga Insights - Nov 6, 2023, 10:30AM

Friday, November 03, 2023

Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Piero Cingari - Nov 3, 2023, 4:03PM

Thursday, November 02, 2023

This Is What Whales Are Betting On Gilead Sciences
Benzinga Insights - Nov 2, 2023, 3:20PM
CORRECTION: Gildan Activewear Ticker Is 'GIL'
Benzinga Newsdesk - Nov 2, 2023, 1:02PM
Gilead And Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit And Showcasing Latest Advances In Blood Cancer Portfolio At ASH 2023
Benzinga Newsdesk - Nov 2, 2023, 9:25AM

Tuesday, October 31, 2023

Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook
Anusuya Lahiri - Oct 31, 2023, 9:06AM
Kite (A Gilead Company) And Epic Bio Announce Collaboration To Develop New Therapies For Cancer
Benzinga Newsdesk - Oct 31, 2023, 7:35AM

Tuesday, October 24, 2023

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Oct 24, 2023, 1:35PM

Friday, October 20, 2023

Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry
Benzinga Insights - Oct 20, 2023, 12:02PM
Gilead Sciences Says It Presented New Data At 19th European AIDS Conference That Further Demonstrates Strong Clinical Profile Of Twice-Yearly Sunlenca For Adults With Multi-Drug Resistant HIV
Benzinga Newsdesk - Oct 20, 2023, 5:15AM

Thursday, October 19, 2023

Gilead Reports In 13G Filing A 6.7% Stake In Ikena Oncology
Benzinga Newsdesk - Oct 19, 2023, 3:38PM
Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase
Vandana Singh - Oct 19, 2023, 8:45AM
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
Lisa Levin - Oct 19, 2023, 7:42AM
Gilead Sciences Announced New Long-Term Real-World Data From The BICSTaR Study Highlighting The Safety And Efficacy Profile Of Biktarvy®
Benzinga Newsdesk - Oct 19, 2023, 3:33AM

Wednesday, October 18, 2023

Hookipa Pharma Announced That The Journal Of Infectious Diseases Has Published Preclinical Data On HB-400, An Investigational Therapeutic Vaccine For Chronic Hepatitis B Developed In Collaboration With Gilead Sciences
Benzinga Newsdesk - Oct 18, 2023, 7:05AM
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Benzinga Newsdesk - Oct 18, 2023, 3:12AM

Tuesday, October 17, 2023

Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why
Vandana Singh - Oct 17, 2023, 9:51AM
Under The Partnership Terms, Assembly Bio's $100M From Gilead Consists Of $84.8M Upfront Payment And $15.2M Equity Investment From Gilead At Premium Of 19.9%
Benzinga Newsdesk - Oct 17, 2023, 7:43AM
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
Benzinga Newsdesk - Oct 17, 2023, 7:41AM

Monday, October 16, 2023

Gilead Sciences Will Present New Data, Including Three Oral Presentations, At The European Society For Medical Oncology Congress 2023
Benzinga Newsdesk - Oct 16, 2023, 7:34AM
Gilead To Provide An Update On Its Signature Initiatives, Key Collaborations And Share New Scientific Data From HIV Research And Development Programs At 19th European AIDS Conference
Benzinga Newsdesk - Oct 16, 2023, 3:45AM

Friday, October 13, 2023

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Benzinga Insights - Oct 13, 2023, 4:00PM
Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles
The Bamboo Works - Oct 13, 2023, 9:32AM

Thursday, October 05, 2023

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Benzinga Insights - Oct 5, 2023, 1:30PM

Tuesday, October 03, 2023

Gilead To Present Latest Innovative Virology Data On Current And Potentially Transformative Therapies Across HIV And Covid-19 At IDweek 2023
Benzinga Newsdesk - Oct 3, 2023, 8:32AM

Friday, September 29, 2023

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Sep 29, 2023, 1:35PM

Thursday, September 28, 2023

Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study
Vandana Singh - Sep 28, 2023, 1:35PM

Open-	Close-
Vol / Avg.77.000 / 5.717M	Mkt Cap95.509B
Day Range- - -	52 Wk Range72.866 - 89.610

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Gilead Sciences Stock (NASDAQ:GILD)

Wednesday, November 29, 2023

Tuesday, November 28, 2023

Wednesday, November 22, 2023

Tuesday, November 21, 2023

Friday, November 17, 2023

Wednesday, November 15, 2023

Tuesday, November 14, 2023

Thursday, November 09, 2023

Wednesday, November 08, 2023

Tuesday, November 07, 2023

Monday, November 06, 2023

Friday, November 03, 2023

Thursday, November 02, 2023

Tuesday, October 31, 2023

Tuesday, October 24, 2023

Friday, October 20, 2023

Thursday, October 19, 2023

Wednesday, October 18, 2023

Tuesday, October 17, 2023

Monday, October 16, 2023

Friday, October 13, 2023

Thursday, October 05, 2023

Tuesday, October 03, 2023

Friday, September 29, 2023

Thursday, September 28, 2023